Deciphex, a Dublin, Ireland-based AI-powered digital precision pathology company, raised €31 million in Series C funding.
Molten Ventures led the investment round with participation from ACT Venture Capital, Seroba, Charles River Laboratories (NYSE: CRL), IRRUS Investments, HBAN Medtech Syndicate, and Nextsteps Capital.
Deciphex said it plans to use the fresh funds to scale up its global service reach, accelerate its pathology AI foundational model development efforts; bolster its partnerships with healthcare industry leaders, and augment its services to Pharma/Biotech and CRO clients.
Based in Dublin, Ireland, Deciphex is building a global network of AI-empowered pathologists, ensuring accessible, innovative pathology services that improve patient outcomes.
Deciphex offers an AI-powered software platform that integrates directly with existing healthcare systems, reducing pathology wait times from 2 months to 2 days. By automating routine pathology workflows, the platform enables pathologists to focus on complex cases while delivering faster, more reliable diagnoses.
“This investment accelerates our mission to transform global pathology access. Our ergonomic, AI-enabled platform enhances diagnostic workflow and accuracy – allowing experts to clear backlogs faster without compromising quality. By expanding this technology worldwide, we’re not just improving healthcare efficiency, we’re supporting both the pathologists who drive diagnoses and the patients who depend on them,” stated Donal O’Shea, founder and CEO of Deciphex, in an official press announcement.